Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HPGDS | O60760 | 6/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL619404 | 0.94 | HPGD (0.47) | HPGDHPGDSKMT2AMEN1NPC1 | |
| SCHEMBL619652 | 0.94 | HPGD (0.44) | HPGDHPGDSKMT2AMEN1NPC1 | |
| SCHEMBL622667 | 0.94 | HPGD (0.44) | HPGDKMT2AMEN1NPC1RAB9A | |
| SCHEMBL622735 | 0.93 | HPGD (0.44) | HPGDHPGDSKMT2AMEN1NPC1 | |
| SCHEMBL622117 | 0.93 | HPGD (0.48) | HPGDHPGDSKMT2AMEN1NPC1 | |
| SCHEMBL622012 | 0.92 | HPGD (0.43) | HPGDHPGDSKMT2AMEN1NPC1 | |
| SCHEMBL622728 | 0.92 | HPGD (0.42) | HPGDHPGDSKMT2AMEN1NPC1 | |
| SCHEMBL619993 | 0.91 | HPGD (0.45) | HPGDKMT2AMEN1NPC1RAB9A | |
| SCHEMBL622668 | 0.90 | HPGD (0.44) | HPGDKMT2AMEN1NPC1RAB9A | |
| SCHEMBL622660 | 0.89 | HPGD (0.47) | HPGDHPGDSKMT2AMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040957-A1 | Novel Bicyclic Antibiotics | BASILEA PHARMACEUTICA AG | 2012-02-16 | — | — | US | disclosed |
| EP-2389376-A1 | NOVEL BICYCLIC ANTIBIOTICS | Basilea Pharmaceutica AG (CH) | 2011-11-30 | — | — | EP | disclosed |
| WO-2010084152-A1 | NOVEL BICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040957-A1 | Novel Bicyclic Antibiotics | C5, C1S, CBR3 | HPGD 3555/4885HPGDS 3655/4885KMT2A 3611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.